Internal medicine

SREE CHAGUTURU, MD, CHIEF MEDICAL OFFICER, CVS HEALTH, BECOMES CHAIR OF THE AMERICAN TELEMEDICINE ASSOCIATION BOARD OF DIRECTORS

Retrieved on: 
星期五, 五月 3, 2024
Nexus, Alpert Medical School, CVS, DNP, FAAN, Mass, Hospital, Policy, Health, PBM, Internal medicine, MD, Brown University, CVS Health, Patient safety, Telehealth, Medicine, CVS Caremark, American Telemedicine Association, Biology, Mass General Brigham, ATA, Massachusetts General Hospital, COVID-19

WASHINGTON, May 3, 2024 /PRNewswire/ -- The American Telemedicine Association (ATA) today announced that Sree Chaguturu, MD, has become Chair of the Board of Directors.

Key Points: 
  • WASHINGTON, May 3, 2024 /PRNewswire/ -- The American Telemedicine Association (ATA) today announced that Sree Chaguturu, MD, has become Chair of the Board of Directors.
  • Dr. Chaguturu is Executive Vice President and Chief Medical Officer, CVS Health®, where he leads the enterprise medical affairs organization spanning across all segments: Aetna®, CVS HealthSpire®, CVS Pharmacy®.
  • Dr. Chaguturu becomes ATA Chair of the Board beginning immediately, succeeding Kristi Henderson, DNP, FAAN, CEO, Confluent Health.
  • Before joining CVS Health, Sree was chief population health officer of Mass General Brigham, the largest health care system in Massachusetts.

AISAP Raises $13 Million in Seed Funding for First AI-Powered, Point Of Care Ultrasound Diagnostic Solution

Retrieved on: 
星期四, 五月 2, 2024
Emergency department, Mayo Clinic, Deep learning, Jefferson Health, TEL, Mossad, Death, Cyber, Life, Intelligence, Sheba Medical Center, Echocardiography, IDL, Patient, POCUS, Financial services, Diagnosis, Internal medicine, Algorithm, Ultrasound, Medical imaging

TEL AVIV, Israel, May 2, 2024 /PRNewswire/ --  AISAP, whose AI-powered Point Of Care Assisted Diagnosis (POCAD)™ solution is transforming the medical ultrasound industry, announced its seed funding round today. The company secured $13 million, led by Harel Insurance Investments & Financial Services Ltd. and Shoni Top Ventures, L.P.

Key Points: 
  • AISAP's POCAD™ solution solves this challenge by providing AI-powered diagnoses that are both highly accurate and easy for any physician to understand – not just ultrasound experts.
  • Unlike most other POCUS devices, AISAP's POCAD™ solution can even provide detailed, accurate diagnoses of specific valves within the cardiovascular systems.
  • And while the average ultrasound takes weeks on average to provide a full analysis and diagnosis, AISAP's solution does so in as little as 5 minutes.
  • In 29% of those cases, the AISAP solution discovered at least one previously-unknown, moderate medical condition.

Avel eCare Acquires Hospitalist Telemedicine Provider 'Horizon Virtual'

Retrieved on: 
星期四, 五月 2, 2024
Hospital, ECARE, Telehealth, Terence Dickinson, Internal medicine, Friends, Nursing, Patient, Acquisition, Hospital medicine, Medical director

SIOUX FALLS, S.D., May 2, 2024 /PRNewswire/ -- Avel eCare, the nation's leading provider of clinician-to-clinician telemedicine services, continues to expand its nationwide leadership in telemedicine with the acquisition of Horizon Virtual, a Minnesota-based virtual hospitalist services provider. The deal marks Avel's 3rd acquisition in just over a year as the company continues its aggressive growth strategy into 2024. 

Key Points: 
  • SIOUX FALLS, S.D., May 2, 2024 /PRNewswire/ -- Avel eCare , the nation's leading provider of clinician-to-clinician telemedicine services, continues to expand its nationwide leadership in telemedicine with the acquisition of Horizon Virtual, a Minnesota-based virtual hospitalist services provider.
  • Acquiring Horizon Virtual represents an exciting opportunity to augment our hospitalist services, which remains one of our fastest-growing service lines," said Doug Duskin, CEO of Avel eCare.
  • Dr. Willardsen will serve as Vice President of Provider Relations and Strategic Partnership at Avel.
  • Dr. Todd Severnak will serve as the Medical Director for the combined Hospitalist service at Avel.

Concert Announces Clinical Advisory Board, New Medical Policies

Retrieved on: 
星期三, 五月 1, 2024
Cepheid variable, FDA, Biochemistry, Doctor of Philosophy, Cardiovascular disease, Vanderbilt University Medical Center, Associate, Palmetto, Prevalence, Concert, Global health, Congress, COVID, CRS, Food, Princeton University, Yale University, DRS, Duke University, Microbiology, Infection, Assistant, Molecular biology, Humana, Staphylococcus, Congressional Research Service, MD–PhD, Health, Library, Neuroscience, Research, Personalized medicine, Emory School, Public policy, Immunology, Medicine, Health policy, Maryland School, Government, Division, Rice University, University, Goucher College, Public health, MD, Duke, Staphylococcus aureus, Wake Forest University, Patient, Internal medicine

NASHVILLE, Tenn., May 1, 2024 /PRNewswire/ -- As part of its commitment to provide transparent, evidence-based medical policy and enable accurate reimbursement for a broader set of diagnostic services, Concert today announced the establishment of an advisory board of experts in clinical laboratory medicine and the release of policies for an expanded scope of routine and advanced laboratory testing.

Key Points: 
  • The newly formed board will advise Concert on its clinical laboratory content.
  • "Concert is working to align payers, providers, and labs to enable patient access to evidence-based testing," said Dr. Girish Putcha.
  • Following are brief bios on each member of the new clinical advisory board, in alphabetical order by last name.
  • Recent roles include Director of Laboratory Science at Palmetto's MolDX program, Chief Medical Officer and Clinical Laboratory Director of Freenome, and Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) member.

Chang Gung Memorial Hospital, Linkou, Garners Two Prestigious International Awards for Its Outstanding Achievements

Retrieved on: 
星期二, 四月 30, 2024
Investment, International Medical Center, Hospital, AI, Proton therapy, Bed, Internal medicine, Pediatrics, Lymphedema, EMRAM, Research, Organ transplantation, Patient safety, Gynaecology, Accreditation, HIMSS, Patient, JCI, Health, Multimedia, Patient satisfaction, Medicine, Nursing

TAOYUAN, April 29, 2024 /PRNewswire/ -- The Healthcare Asia Awards, a prestigious international recognition program, honors exceptional healthcare institutions across Asia for their pioneering achievements in healthcare innovation and patient care. On March 26th, at the 2024 Awards Ceremony held in Singapore, Chang Gung Memorial Hospital, Linkou, Taiwan, emerged victorious, capturing the coveted titles of Hospital of the Year - Taiwan and Smart Hospital Initiative of the Year - Taiwan.

Key Points: 
  • With over 30 departments, Chang Gung Memorial Hospital offers a broad spectrum of services, including internal medicine, surgery, gynecology, and pediatrics.
  • Chang Gung Memorial Hospital not only excels in medical technology and services but also prioritizes patient safety and compassionate care.
  • This year, the Healthcare Asia Awards acknowledged Chang Gung Memorial Hospital in Linkou for its exceptional leadership in medical services, research, and smart healthcare innovations.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/chang-gung-memorial-hospital-li...
    SOURCE Chang Gung Memorial Hospital, Linkou

Two South Florida Doctors Open New MDVIP-Affiliated Primary Care Practices

Retrieved on: 
星期一, 四月 29, 2024
Patient, Obesity medicine, Nursing care plan, Pharmacy, Health, Anesthesiology, Insomnia, Physician, Medicare, Internal medicine, MDVIP, Nursing

BOCA RATON, Fla., April 29, 2024 /PRNewswire/ -- MDVIP, the market leader in personalized healthcare with a network of over 1,100 physicians nationwide, today announced the opening of two new MDVIP-affiliated practices in South Florida. Emily Salmon-Denikos, M.D., a family physician in Lake Worth, and Dimitri M. Gitelmaker, M.D., a board-certified internist and obesity medicine specialist in Hollywood, have each joined the MDVIP network and are currently accepting patients who want a more direct relationship with their primary care doctor.

Key Points: 
  • , a board-certified internist and obesity medicine specialist in Hollywood, have each joined the MDVIP network and are currently accepting patients who want a more direct relationship with their primary care doctor.
  • MDVIP-affiliated physicians offer a solution to the many frustrations that patients can experience with traditional primary care, including long waits to schedule an appointment, rushed visits and difficulty getting all of their concerns addressed.
  • "With experience in anesthesiology and critical care, I am well versed in pulmonary and cardiac health.
  • Eleven peer-reviewed, published studies show that patients in MDVIP-affiliated practices have better health outcomes compared to those in traditional primary care practices, including:
    79% fewer hospitalizations for Medicare patients, equating to $600 million savings in one year

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity

Retrieved on: 
星期五, 五月 3, 2024
FDA, Upjohn, Cytoprotection, Research, Geriatrics, Trial of the century, Doctor of Philosophy, IND, Hepatology, Prostaglandin, Baylor University, SAB, Endocrinology, Baylor College of Medicine, Ageing, Diabetes, Euronext Growth, Gastroenterology, Wellcome Research Laboratories, Obesity, Therapy, Royal Free Hospital, Notifiable disease, Investigational New Drug, OBA, GLP1, Frailty, Consultant, MD, Facial muscles, Digestion, Patient, Metabolism, Sarcopenia, Internal medicine, Pharmaceutical industry

The OBA SAB will guide the company to develop BIO101 (20-hydroxyecdysone) in obesity, in combination with GLP1-RA, and will actively work towards the finalization of the OBA Phase 2 clinical study design.

Key Points: 
  • The OBA SAB will guide the company to develop BIO101 (20-hydroxyecdysone) in obesity, in combination with GLP1-RA, and will actively work towards the finalization of the OBA Phase 2 clinical study design.
  • Biophytis plans to file for an Investigational New Drug (IND) application to start the OBA Phase 2 clinical study in the USA with FDA in the coming weeks.
  • Stanislas Veillet, CEO de Biophytis states: “We are pleased to announce the appointment of Professor Dennis Villareal and Professor Francisco Guarner to the Scientific Advisory Board of the OBA Phase 2 study.
  • We are preparing with the SAB to file for an IND to start the OBA phase 2 clinical study in the coming weeks.”
    The first two members of Biophytis’ new Scientific Advisory Board for the OBA clinical study are:
    at Baylor College of Medicine, Houston, Texas, United States.

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

Retrieved on: 
星期四, 五月 2, 2024
Infection, MASH, Liver disease, Cirrhosis, NAFLD, American Gastroenterological Association, NIH, Publication, Research, Cell Metabolism, Yale University, American Liver Foundation, KOL, Journal of Clinical Pathology, Journal, NASH, Virginia Commonwealth University, Liver, Patient, Fibrosis, AASLD, Internal medicine, Medical Center, Division, SAN, VCU, Pharmaceutical industry

The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH.

Key Points: 
  • The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH.
  • A replay of the webinar will be accessible in the investors section of 89bio’s website following the event.
  • He has also served as Secretary as well as President of the American Association for the Study of Liver Diseases.
  • He has been continuously funded by the NIH since 1995 and is the principal investigator of four active NIH grants.

Targeted Oncology™ announces first recipient of 2024 for its Oncology Icons award program

Retrieved on: 
星期二, 四月 23, 2024
Organization, Learning, Hematology, Internal medicine, Oncology, University School, Science, Patient, Internet, Medicine, Multimedia, Therapy, Biology, Samma (tribe), Louisiana State University, Cancer, Nursing

CRANBURY, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of oncology, is thrilled to announce the newest recipient of the Oncology Icons award program.

Key Points: 
  • CRANBURY, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of oncology, is thrilled to announce the newest recipient of the Oncology Icons award program.
  • This program recognizes individuals who have made exceptional contributions to the field of oncology through their expertise, dedication and innovation.
  • He is triple-board-certified in hematology, medical oncology and internal medicine by the American Board of Internal Medicine.
  • Submissions for the next 2024 Targeted Oncology Icons Award are open.

Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome

Retrieved on: 
星期一, 四月 22, 2024
GRACE, Hyperglycemia, University, Patient, Syndrome, SBP, Adrenal insufficiency, Safety, NDA, Waist, Ann Arbor, Michigan, MD, Doctor of Philosophy, Vaginal bleeding, DSM-IV codes, Doctor of Pharmacy, Diabetes, Hypertension, Metabolism, Internal medicine, Endocrinology, Division, Deficit spending, DBP, Pharmaceutical industry

In the “open-label” phase, 152 patients with Cushing’s syndrome and either hypertension, hyperglycemia or both received relacorilant for 22 weeks.

Key Points: 
  • In the “open-label” phase, 152 patients with Cushing’s syndrome and either hypertension, hyperglycemia or both received relacorilant for 22 weeks.
  • GRACE’s primary endpoint is maintenance of blood pressure control in the “randomized withdrawal” phase, with maintenance of glycemic control as the key secondary endpoint.
  • Other key secondary and exploratory endpoints in the randomized withdrawal phase include changes in weight, waist circumference, cognitive impairment and Cushing’s Quality of Life score.
  • Patients in the open-label phase exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints.